• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intensifying daunorubicin in induction for patients with core binding factor leukemia.

作者信息

Dobashi Nobuaki, Yamaguchi Yuko, Asai Osamu, Yano Shingo, Osawa Hiroshi, Yahagi Yuichi, Takei Yutaka, Sugiyama Katsuki, Saito Takeshi, Usui Noriko

出版信息

Int J Hematol. 2006 Dec;84(5):463-4. doi: 10.1532/IJH97.06138.

DOI:10.1532/IJH97.06138
PMID:17189231
Abstract
摘要

相似文献

1
Intensifying daunorubicin in induction for patients with core binding factor leukemia.
Int J Hematol. 2006 Dec;84(5):463-4. doi: 10.1532/IJH97.06138.
2
A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.一项关于比较伊达比星与柔红霉素（或其他蒽环类药物）作为急性髓系白血病诱导治疗的随机试验的系统协作综述。急性髓系白血病协作组。
Br J Haematol. 1998 Oct;103(1):100-9.
3
[Results of clinical trials in the treatment of acute myeloid leukemia in adults during a 7-year period].
Ter Arkh. 1999;71(7):13-20.
4
Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.增加蒽环类抗生素的剂量强度可改善急性髓性白血病患者的预后。
Am J Hematol. 2004 Aug;76(4):319-29. doi: 10.1002/ajh.20120.
5
Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.对于接受统一强化治疗的60岁及以上急性髓系白血病患者，疾病生物学而非年龄是生存的最重要决定因素。
Cancer. 2005 May 15;103(10):2082-90. doi: 10.1002/cncr.21006.
6
Comparison of 60 and 80 mg/m of daunorubicin in induction therapy of acute myeloid leukaemia.柔红霉素60mg/m²和80mg/m²用于急性髓系白血病诱导治疗的比较。
Hematol Oncol. 2017 Mar;35(1):101-105. doi: 10.1002/hon.2236. Epub 2015 Aug 3.
7
Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.
Leukemia. 2002 Sep;16(9):1880-1. doi: 10.1038/sj.leu.2402617.
8
Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.使用不含阿糖胞苷的伊达比星、依托泊苷和卡铂方案对初治急性髓系白血病进行缓解诱导治疗。
Cancer. 1998 Oct 1;83(7):1344-54.
9
Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.在成人急性髓性白血病的诱导和巩固联合治疗中，比较山嵛酰阿糖胞苷与阿糖胞苷的随机试验，以及在维持/强化治疗后加用或不加用乌苯美司的随机试验。日本白血病研究组。
J Clin Oncol. 1996 Jan;14(1):204-13. doi: 10.1200/JCO.1996.14.1.204.
10
Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.柔红霉素在成人急性髓系白血病诱导治疗中的作用。
J Clin Oncol. 1998 Jun;16(6):2086-92. doi: 10.1200/JCO.1998.16.6.2086.

引用本文的文献

1
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.用于儿童癌症治疗时，含蒽环类药物的治疗方案与不含蒽环类药物的治疗方案对比。
Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD006647. doi: 10.1002/14651858.CD006647.pub4.

本文引用的文献

1
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.基于个体患者数据的16至60岁核心结合因子急性髓系白血病患者的荟萃分析：德国急性髓系白血病协作组的一项调查
J Clin Oncol. 2004 Sep 15;22(18):3741-50. doi: 10.1200/JCO.2004.03.012. Epub 2004 Aug 2.
2
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.高剂量阿糖胞苷重复疗程对急性髓系白血病伴inv(16)(p13q22)或t(16;16)(p13;q22)患者有益：癌症和白血病B组8461研究结果
J Clin Oncol. 2004 Mar 15;22(6):1087-94. doi: 10.1200/JCO.2004.07.012.
3
Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemia.
成人急性髓性白血病诱导治疗中强化柔红霉素及缓解后治疗中自体外周血干细胞移植（双7方案）
Int J Hematol. 2002 Dec;76(5):436-45. doi: 10.1007/BF02982809.
4
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.患有t(8;21)(q22;q22)且患有急性髓性白血病的患者在接受高剂量阿糖胞苷的重复疗程时，无失败生存期和总生存期更佳。
J Clin Oncol. 1999 Dec;17(12):3767-75. doi: 10.1200/JCO.1999.17.12.3767.
5
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.急性髓系白血病大剂量阿糖胞苷强化治疗后长期缓解持续时间的频率因细胞遗传学亚型而异。
Cancer Res. 1998 Sep 15;58(18):4173-9.
6
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.诊断细胞遗传学对急性髓系白血病预后的重要性：对参加医学研究委员会AML 10试验的1612例患者的分析。医学研究委员会成人及儿童白血病工作组。
Blood. 1998 Oct 1;92(7):2322-33.
7
Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.柔红霉素在成人急性髓系白血病诱导治疗中的作用。
J Clin Oncol. 1998 Jun;16(6):2086-92. doi: 10.1200/JCO.1998.16.6.2086.